Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8083275 | 0.92 | CYP19A1 (0.49) | CYP19A1CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL8083240 | 0.91 | CYP19A1 (0.49) | CYP19A1CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL9626851 | 0.85 | CYP19A1 (0.49) | CYP19A1 | |
| SCHEMBL7030182 | 0.85 | CYP19A1 (0.49) | CYP19A1 | |
| SCHEMBL6853055 | 0.82 | CYP19A1 (0.51) | CYP19A1 | |
| SCHEMBL3660113 | 0.76 | CYP19A1 (0.58) | CYP19A1 | |
| SCHEMBL6904362 | 0.74 | LMNA (0.53) | CYP19A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7028398 | 0.74 | LMNA (0.53) | CYP19A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8892914 | 0.74 | LMNA (0.53) | CYP19A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7702632 | 0.74 | CYP19A1 (0.36) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0906332-B1 | 7ALPHA-(5-METHYLAMINOPENTYL)-ESTRATRIENES, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS WHICH CONTAIN SAID 7ALPHA-(5-METHYLAMINOPENTYL)-ESTRATRIENES AND USE THEREOF FOR PRODUCTION OF DRUGS | SCHERING AG (DE) | 2001-11-28 | — | — | EP | disclosed |
| US-6288051-B1 | ESTROGEN-DEPENDENT BREAST CANCER TREATMENT | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |